Clinical Trial: Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid
Brief Summary: We suggest treating the Hutchinson-Gilford Progeria Syndrome by two molecules (zoledronic acid and pravastatin).The therapeutic approach which we propose has for objectives to reduce, to prevent or to delay the gravest infringements of the disease, to prolong the life of the children, and in a more general way, aim at improving their living conditions.
Detailed Summary:
Sponsor: Assistance Publique Hopitaux De Marseille
Current Primary Outcome: To evaluate the tolerance and efficacy of pravastatin and zoledronic acid in combination on the patient's weight, height and bone metabolism in Progeria treatment [ Time Frame: 48 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome: To evaluate the tolerance and efficacy of the treatment on other clinical and biological symptoms [ Time Frame: 48 months ]
Original Secondary Outcome: Same as current
Information By: Assistance Publique Hopitaux De Marseille
Dates:
Date Received: August 1, 2008
Date Started: October 2008
Date Completion:
Last Updated: July 4, 2013
Last Verified: July 2013